Sales grew 4.3% year-over-year to CHF 326.4 million, with strong gains in clinical development and research segments, but profitability was impacted by ramp-up costs for new facilities. Outlook for 2026 is robust, with projected sales growth of 35–40% and major investments planned.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.